ClinicalTrials.gg
CompletedNCT00751179Updated Jun 30, 2015Results posted

Rocuronium Plus Sugammadex Versus Succinylcholine Alone in Participants Undergoing Short Surgical Procedures (19.4.319)(P05700 AM2)(COMPLETED)

A Phase 3 interventional study of rocuronium and sugammadex in Neuromuscular Blockade, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-06-30.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
161
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

A multi-center, randomized, parallel group, comparative, active controlled, safety assessor blinded trial in adult subjects comparing rocuronium plus sugammadex versus succinylcholine alone in subjects undergoing short surgical procedures in out-patient surgicenters. The primary objective was to evaluate changes in plasma potassium levels after treatment with rocuronium, sugammadex, or succinylcholine in adult subjects scheduled for short surgical procedures in out-patient surgicenters.

02

Conditions studied

  • Neuromuscular Blockade
03

In context

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subjects >=18 years of age;
  • ASA Class 1-3;
  • Subjects with a (BMI) of \< 35 kg/m\^2 ;
  • Subjects scheduled to undergo an elective short procedure with general anesthesia requiring neuromuscular relaxation and endotracheal intubation in outpatient surgicenters;
  • Subjects scheduled to undergo an elective surgical procedure expected to last 1.5 hours or less (from end of intubation to end of suturing/stapling of skin);
  • Subjects who are scheduled to undergo an elective surgical procedures that allows access to the arm for TOF-Watch® SX monitoring;
  • Subjects who have given written .

Exclusion criteria

Exclusion Criteria:

  • Subjects known to have ischemic heart disease or a history of myocardial infarction;
  • Subjects in whom a difficult intubation is expected because of anatomical malformations;
  • Subjects with medical conditions and/or undergoing surgical procedures that are not compatible with the use of the TOF-Watch SX (e.g., injuries to the thumbs/distal forearms, bilateral ulnar nerve damage or subjects with cardiac pacemakers);
  • Subjects known or suspected to have neuromuscular disorders impairing neuromuscular blockade (e.g., subjects with myasthenia gravis);
  • Subjects who would require the use of pneumatic tourniquet during the surgical procedure;
  • Subjects known or suspected to have significant renal dysfunction (e.g., \< 30 mL per min);
  • Subjects known or suspected to have significant hepatic dysfunction;
  • Subjects known or suspected to have a (family) history of malignant hyperthermia;
  • Subjects known or suspected to be hypersensitive to sugammadex or other cyclodextrins or rocuronium or any of its ;
  • Subjects known or suspected to have an allergy to opiates/opioids, muscle relaxants, or other medications used during general anesthesia;
  • Subjects for whom a pre-established need for post operative intensive care admission and/or hospital admission is expected;
  • Subjects for whom an intra operative IV administration of fluids that contain potassium is expected;
  • Female subjects who are pregnant;
  • Female subjects who are breast-feeding;
  • Subjects who have participated in a previous sugammadex trial;
  • Subjects who have participated in another drug trial within 30 days before entering into clinical trial (CT) 19.4.319 (P05700) unless pre-approved by the sponsor.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
161 participants (actual)

Study arms

  • Active comparator
    Rocuronium - Sugammadex

    Rocuronium - Sugammadex 4.0 mg/kg

    Drug: rocuronium · Drug: sugammadex

  • Active comparator
    Succinylcholine

    Succinylcholine 1.0 mg/kg

    Drug: succinylcholine

Interventions

  • A single bolus intubation dose of 0.6 mg/kg rocuronium will be administered following induction of anesthesia and if required, single bolus dose(s) of 0.15 mg/kg rocuronium will be administered to maintain the neuromuscular block.

    Also known as: Zemuron® Injection (rocuronium bromide)

  • At the end of the surgical procedure at a target depth of neuromuscular blockade of at least 1-2 Post-Tetanic Count (PTC), 4.0 mg/kg of sugammadex will be administered.

    Also known as: sugammadex sodium injection, SCH 900916, Org 25969, Bridion

  • A single bolus intubation dose of 1.0 mg/kg succinylcholine will be administered following induction of anesthesia and the subject is allowed to recover spontaneously from the neuromuscular blockade.

    Also known as: Quelicin® (succinylcholine chloride injection United States Pharmacopeia [USP])

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Plasma Potassium Levels at 5 Minutes After Treatment With Rocuronium or Succinylcholine

    Change from baseline = 5 minutes post dose value - baseline value. Baseline levels were obtained prior to rocuronium or succinylcholine dose. Only data post rocuronium dose are included for "rocuronium - sugammadex" group. The change from baseline interval included most or all of the intubation/surgical period for sugammadex analysis (since sugammadex was administered at the end of the surgical procedure) but not for succinylcholine or rocuronium analyses (since these were administered immediately after the baseline measurement just prior to intubation/commencement of the surgical period).

    Time frame: Baseline and 5 minutes post dose

  2. Change From Baseline in Plasma Potassium Levels at 5 Minutes After Treatment With Sugammadex

    Change from baseline = 5 minutes post dose value - baseline value. Baseline levels were obtained prior to rocuronium dose. Only data post sugammadex dose are included for "rocuronium - sugammadex" group. The change from baseline interval included most or all of the intubation/surgical period for sugammadex analysis (since sugammadex was administered at the end of the surgical procedure) but not for succinylcholine or rocuronium analyses (since these were administered immediately after the baseline measurement just prior to intubation/commencement of the surgical period).

    Time frame: Baseline and 5 minutes post dose

Secondary outcomes

  1. Change From Baseline in Plasma Potassium Levels at 2 Minutes After Treatment With Rocuronium or Succinylcholine

    Change from baseline = 2 minutes post dose value - baseline value. Baseline levels were obtained prior to rocuronium or succinylcholine dose. Only data post rocuronium dose are included for "rocuronium - sugammadex" group. The change from baseline interval included most or all of the intubation/surgical period for sugammadex analysis (since sugammadex was administered at the end of the surgical procedure) but not for succinylcholine or rocuronium analyses (since these were administered immediately after the baseline measurement just prior to intubation/commencement of the surgical period).

    Time frame: Baseline and 2 minutes post dose

  2. Change From Baseline in Plasma Potassium Levels at 2 Minutes After Treatment With Sugammadex

    Change from baseline = 2 minutes post dose value - baseline value. Baseline levels were obtained prior to rocuronium dose. Only data post sugammadex dose are included for "rocuronium - sugammadex" group. The change from baseline interval included most or all of the intubation/surgical period for sugammadex analysis (since sugammadex was administered at the end of the surgical procedure) but not for succinylcholine or rocuronium analyses (since these were administered immediately after the baseline measurement just prior to intubation/commencement of the surgical period).

    Time frame: Baseline and 2 minutes post dose

  3. Change From Baseline in Plasma Potassium Levels at 10 Minutes After Treatment With Rocuronium or Succinylcholine

    Change from baseline = 10 minutes post dose value - baseline value. Baseline levels were obtained prior to rocuronium or succinylcholine dose. Only data post rocuronium dose are included for "rocuronium - sugammadex" group. The change from baseline interval included most or all of the intubation/surgical period for sugammadex analysis (since sugammadex was administered at the end of the surgical procedure) but not for succinylcholine or rocuronium analyses (since these were administered immediately after the baseline measurement just prior to intubation/commencement of the surgical period).

    Time frame: Baseline and 10 minutes post dose

  4. Change From Baseline in Plasma Potassium Levels at 10 Minutes After Treatment With Sugammadex

    Change from baseline = 10 minutes post dose value - baseline value. Baseline levels were obtained prior to rocuronium dose. Only data post sugammadex dose are included for "rocuronium - sugammadex" group. The change from baseline interval included most or all of the intubation/surgical period for sugammadex analysis (since sugammadex was administered at the end of the surgical procedure) but not for succinylcholine or rocuronium analyses (since these were administered immediately after the baseline measurement just prior to intubation/commencement of the surgical period).

    Time frame: Baseline and 10 minutes post dose

  5. Change From Baseline in Plasma Potassium Levels at 15 Minutes After Treatment With Rocuronium or Succinylcholine

    Change from baseline = 15 minutes post dose value - baseline value. Baseline levels were obtained prior to rocuronium or succinylcholine dose. Only data post rocuronium dose are included for "rocuronium - sugammadex" group. The change from baseline interval included most or all of the intubation/surgical period for sugammadex analysis (since sugammadex was administered at the end of the surgical procedure) but not for succinylcholine or rocuronium analyses (since these were administered immediately after the baseline measurement just prior to intubation/commencement of the surgical period).

    Time frame: Baseline and 15 minutes post dose

  6. Change From Baseline in Plasma Potassium Levels at 15 Minutes After Treatment With Sugammadex

    Change from baseline = 15 minutes post dose value - baseline value. Baseline levels were obtained prior to rocuronium dose. Only data post sugammadex dose are included for "rocuronium - sugammadex" group. The change from baseline interval included most or all of the intubation/surgical period for sugammadex analysis (since sugammadex was administered at the end of the surgical procedure) but not for succinylcholine or rocuronium analyses (since these were administered immediately after the baseline measurement just prior to intubation/commencement of the surgical period).

    Time frame: Baseline and 15 minutes post dose

  7. Number of Participants With at Least One Adverse Event (AE) in Rocuronium - Sugammadex and Succinylcholine Treatment Groups

    Only AEs which occurred following administration of sugammadex or succinylcholine are included. AEs in the rocuronium - sugammadex group occurring after rocuronium but before sugammadex administration are considered "pretreatment" events and are not included. The AE reporting interval included the entire intubation/surgical period for the succinylcholine group (since succinylcholine was administered just prior to intubation/commencement of surgery) but not for the rocuronium - sugammadex group (since sugammadex was administered at the end of the surgical procedure).

    Time frame: Up to 7 days post dose

  8. Time to Recovery of the Fourth Twitch/First Twitch (T4/T1) Ratio to 0.9 Following Administration of 4.0 mg/kg of Sugammadex After Neuromuscular Blockade Induced by Rocuronium

    Neuromuscular functioning was monitored by applying repetitive train of four (TOF) electrical stimulations to the ulnar nerve every 15 seconds and assessing twitch response at the adductor pollicis muscle. Nerve stimulation continued until the ratio of the magnitude of the fourth twitch (T4) to first twitch (T1) reached at least 0.9. The greater the T4/T1 ratio the greater the recovery from neuromuscular blockade, with a value of 1.0 representing full recovery.

    Time frame: Start of administration of sugammadex to recovery from neuromuscular blockade (Up to approximately 6 minutes)

  9. Time to Recovery of T1 to 90% of Baseline Following Neuromuscular Blockade Induced by Succinylcholine

    Neuromuscular functioning was monitored by applying repetitive train of four (TOF) electrical stimulations to the ulnar nerve every 15 seconds and assessing twitch response at the adductor pollicis muscle. Nerve stimulation continued until recovery of T1 of 90% of baseline and full recovery of neuromuscular function occurred as determined by the anesthesiologist as per routine clinical practice.

    Time frame: Start of administration of succinylcholine to recovery from neuromuscular blockade (Up to approximately 18 minutes)

07

Results

Posted Mar 20, 2012
Limitations and caveats
The potassium change from baseline interval included most/all of the intubation/surgical period for the sug but not the suc or roc analysis. AE reporting interval included the entire intubation/surgery period for the suc but not the roc-sug group.

Participant flow

Participant flow — Overall Study
MilestoneRocuronium - SugammadexSuccinylcholine
Started7685
Completed6270
Not completed1415

Outcome measures

PrimaryChange From Baseline in Plasma Potassium Levels at 5 Minutes After Treatment With Rocuronium or Succinylcholine

Change from baseline = 5 minutes post dose value - baseline value. Baseline levels were obtained prior to rocuronium or succinylcholine dose. Only data post rocuronium dose are included for "rocuronium - sugammadex" group. The change from baseline interval included most or all of the intubation/surgical period for sugammadex analysis (since sugammadex was administered at the end of the surgical procedure) but not for succinylcholine or rocuronium analyses (since these were administered immediately after the baseline measurement just prior to intubation/commencement of the surgical period).

Time frame:
Baseline and 5 minutes post dose
Reported as:
Mean · mmol/L
Change From Baseline in Plasma Potassium Levels at 5 Minutes After Treatment With Rocuronium or Succinylcholine
mmol/LRocuronium - SugammadexSuccinylcholine
Change From Baseline in Plasma Potassium Levels at 5 Minutes After Treatment With Rocuronium or Succinylcholine-0.06 ± 0.320.30 ± 0.34
Statistical analysis
  • Rocuronium - Sugammadex vs Succinylcholine · ANOVA · p = <0.0001 (Significance level was set at 0.05.)
SecondaryChange From Baseline in Plasma Potassium Levels at 2 Minutes After Treatment With Rocuronium or Succinylcholine

Change from baseline = 2 minutes post dose value - baseline value. Baseline levels were obtained prior to rocuronium or succinylcholine dose. Only data post rocuronium dose are included for "rocuronium - sugammadex" group. The change from baseline interval included most or all of the intubation/surgical period for sugammadex analysis (since sugammadex was administered at the end of the surgical procedure) but not for succinylcholine or rocuronium analyses (since these were administered immediately after the baseline measurement just prior to intubation/commencement of the surgical period).

Time frame:
Baseline and 2 minutes post dose
Reported as:
Mean · mmol/L
Change From Baseline in Plasma Potassium Levels at 2 Minutes After Treatment With Rocuronium or Succinylcholine
mmol/LRocuronium - SugammadexSuccinylcholine
Change From Baseline in Plasma Potassium Levels at 2 Minutes After Treatment With Rocuronium or Succinylcholine-0.09 ± 0.300.19 ± 0.36
Statistical analysis
  • Rocuronium - Sugammadex vs Succinylcholine · ANOVA · p = <0.0001 (Significance level was set at 0.05.)
SecondaryChange From Baseline in Plasma Potassium Levels at 2 Minutes After Treatment With Sugammadex

Change from baseline = 2 minutes post dose value - baseline value. Baseline levels were obtained prior to rocuronium dose. Only data post sugammadex dose are included for "rocuronium - sugammadex" group. The change from baseline interval included most or all of the intubation/surgical period for sugammadex analysis (since sugammadex was administered at the end of the surgical procedure) but not for succinylcholine or rocuronium analyses (since these were administered immediately after the baseline measurement just prior to intubation/commencement of the surgical period).

Time frame:
Baseline and 2 minutes post dose
Reported as:
Mean · mmol/L
Change From Baseline in Plasma Potassium Levels at 2 Minutes After Treatment With Sugammadex
mmol/LRocuronium - Sugammadex
Change From Baseline in Plasma Potassium Levels at 2 Minutes After Treatment With Sugammadex-0.02 ± 0.39
SecondaryChange From Baseline in Plasma Potassium Levels at 10 Minutes After Treatment With Rocuronium or Succinylcholine

Change from baseline = 10 minutes post dose value - baseline value. Baseline levels were obtained prior to rocuronium or succinylcholine dose. Only data post rocuronium dose are included for "rocuronium - sugammadex" group. The change from baseline interval included most or all of the intubation/surgical period for sugammadex analysis (since sugammadex was administered at the end of the surgical procedure) but not for succinylcholine or rocuronium analyses (since these were administered immediately after the baseline measurement just prior to intubation/commencement of the surgical period).

Time frame:
Baseline and 10 minutes post dose
Reported as:
Mean · mmol/L
Change From Baseline in Plasma Potassium Levels at 10 Minutes After Treatment With Rocuronium or Succinylcholine
mmol/LRocuronium - SugammadexSuccinylcholine
Change From Baseline in Plasma Potassium Levels at 10 Minutes After Treatment With Rocuronium or Succinylcholine-0.01 ± 0.270.32 ± 0.41
Statistical analysis
  • Rocuronium - Sugammadex vs Succinylcholine · ANOVA · p = <0.0001 (Significance level was set at 0.05.)
SecondaryChange From Baseline in Plasma Potassium Levels at 10 Minutes After Treatment With Sugammadex

Change from baseline = 10 minutes post dose value - baseline value. Baseline levels were obtained prior to rocuronium dose. Only data post sugammadex dose are included for "rocuronium - sugammadex" group. The change from baseline interval included most or all of the intubation/surgical period for sugammadex analysis (since sugammadex was administered at the end of the surgical procedure) but not for succinylcholine or rocuronium analyses (since these were administered immediately after the baseline measurement just prior to intubation/commencement of the surgical period).

Time frame:
Baseline and 10 minutes post dose
Reported as:
Mean · mmol/L
Change From Baseline in Plasma Potassium Levels at 10 Minutes After Treatment With Sugammadex
mmol/LRocuronium - Sugammadex
Change From Baseline in Plasma Potassium Levels at 10 Minutes After Treatment With Sugammadex0.07 ± 0.38
SecondaryChange From Baseline in Plasma Potassium Levels at 15 Minutes After Treatment With Rocuronium or Succinylcholine

Change from baseline = 15 minutes post dose value - baseline value. Baseline levels were obtained prior to rocuronium or succinylcholine dose. Only data post rocuronium dose are included for "rocuronium - sugammadex" group. The change from baseline interval included most or all of the intubation/surgical period for sugammadex analysis (since sugammadex was administered at the end of the surgical procedure) but not for succinylcholine or rocuronium analyses (since these were administered immediately after the baseline measurement just prior to intubation/commencement of the surgical period).

Time frame:
Baseline and 15 minutes post dose
Reported as:
Mean · mmol/L
Change From Baseline in Plasma Potassium Levels at 15 Minutes After Treatment With Rocuronium or Succinylcholine
mmol/LRocuronium - SugammadexSuccinylcholine
Change From Baseline in Plasma Potassium Levels at 15 Minutes After Treatment With Rocuronium or Succinylcholine0.02 ± 0.260.33 ± 0.42
Statistical analysis
  • Rocuronium - Sugammadex vs Succinylcholine · ANOVA · p = <0.0001 (Significance level was set at 0.05.)
SecondaryChange From Baseline in Plasma Potassium Levels at 15 Minutes After Treatment With Sugammadex

Change from baseline = 15 minutes post dose value - baseline value. Baseline levels were obtained prior to rocuronium dose. Only data post sugammadex dose are included for "rocuronium - sugammadex" group. The change from baseline interval included most or all of the intubation/surgical period for sugammadex analysis (since sugammadex was administered at the end of the surgical procedure) but not for succinylcholine or rocuronium analyses (since these were administered immediately after the baseline measurement just prior to intubation/commencement of the surgical period).

Time frame:
Baseline and 15 minutes post dose
Reported as:
Mean · mmol/L
Change From Baseline in Plasma Potassium Levels at 15 Minutes After Treatment With Sugammadex
mmol/LRocuronium - Sugammadex
Change From Baseline in Plasma Potassium Levels at 15 Minutes After Treatment With Sugammadex0.07 ± 0.39
PrimaryChange From Baseline in Plasma Potassium Levels at 5 Minutes After Treatment With Sugammadex

Change from baseline = 5 minutes post dose value - baseline value. Baseline levels were obtained prior to rocuronium dose. Only data post sugammadex dose are included for "rocuronium - sugammadex" group. The change from baseline interval included most or all of the intubation/surgical period for sugammadex analysis (since sugammadex was administered at the end of the surgical procedure) but not for succinylcholine or rocuronium analyses (since these were administered immediately after the baseline measurement just prior to intubation/commencement of the surgical period).

Time frame:
Baseline and 5 minutes post dose
Reported as:
Mean · mmol/L
Change From Baseline in Plasma Potassium Levels at 5 Minutes After Treatment With Sugammadex
mmol/LRocuronium - Sugammadex
Change From Baseline in Plasma Potassium Levels at 5 Minutes After Treatment With Sugammadex0.02 ± 0.42
SecondaryNumber of Participants With at Least One Adverse Event (AE) in Rocuronium - Sugammadex and Succinylcholine Treatment Groups

Only AEs which occurred following administration of sugammadex or succinylcholine are included. AEs in the rocuronium - sugammadex group occurring after rocuronium but before sugammadex administration are considered "pretreatment" events and are not included. The AE reporting interval included the entire intubation/surgical period for the succinylcholine group (since succinylcholine was administered just prior to intubation/commencement of surgery) but not for the rocuronium - sugammadex group (since sugammadex was administered at the end of the surgical procedure).

Time frame:
Up to 7 days post dose
Reported as:
Number · participants
Number of Participants With at Least One Adverse Event (AE) in Rocuronium - Sugammadex and Succinylcholine Treatment Groups
participantsRocuronium - SugammadexSuccinylcholine
Number of Participants With at Least One Adverse Event (AE) in Rocuronium - Sugammadex and Succinylcholine Treatment Groups6075
SecondaryTime to Recovery of the Fourth Twitch/First Twitch (T4/T1) Ratio to 0.9 Following Administration of 4.0 mg/kg of Sugammadex After Neuromuscular Blockade Induced by Rocuronium

Neuromuscular functioning was monitored by applying repetitive train of four (TOF) electrical stimulations to the ulnar nerve every 15 seconds and assessing twitch response at the adductor pollicis muscle. Nerve stimulation continued until the ratio of the magnitude of the fourth twitch (T4) to first twitch (T1) reached at least 0.9. The greater the T4/T1 ratio the greater the recovery from neuromuscular blockade, with a value of 1.0 representing full recovery.

Time frame:
Start of administration of sugammadex to recovery from neuromuscular blockade (Up to approximately 6 minutes)
Reported as:
Geometric mean · Minutes
Time to Recovery of the Fourth Twitch/First Twitch (T4/T1) Ratio to 0.9 Following Administration of 4.0 mg/kg of Sugammadex After Neuromuscular Blockade Induced by Rocuronium
MinutesRocuronium - Sugammadex
Time to Recovery of the Fourth Twitch/First Twitch (T4/T1) Ratio to 0.9 Following Administration of 4.0 mg/kg of Sugammadex After Neuromuscular Blockade Induced by Rocuronium1.79 (1.59 to 2.03)
SecondaryTime to Recovery of T1 to 90% of Baseline Following Neuromuscular Blockade Induced by Succinylcholine

Neuromuscular functioning was monitored by applying repetitive train of four (TOF) electrical stimulations to the ulnar nerve every 15 seconds and assessing twitch response at the adductor pollicis muscle. Nerve stimulation continued until recovery of T1 of 90% of baseline and full recovery of neuromuscular function occurred as determined by the anesthesiologist as per routine clinical practice.

Time frame:
Start of administration of succinylcholine to recovery from neuromuscular blockade (Up to approximately 18 minutes)
Reported as:
Geometric mean · Minutes
Time to Recovery of T1 to 90% of Baseline Following Neuromuscular Blockade Induced by Succinylcholine
MinutesSuccinylcholine
Time to Recovery of T1 to 90% of Baseline Following Neuromuscular Blockade Induced by Succinylcholine10.76 (10.06 to 11.52)

Adverse events

Collected over Up to 7 days post dose. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rocuronium - Sugammadex—1/66 (1.5%)57/66 (86.4%)
Succinylcholine—3/80 (3.8%)67/80 (83.8%)
Most frequent serious events
Most frequent serious events
EventRocuronium - SugammadexSuccinylcholine
Procedural nauseaInjury, poisoning and procedural complications1/660/80
Rectal hemorrhageGastrointestinal disorders0/661/80
Medical observationInvestigations0/661/80
Oxygen saturation decreasedInvestigations0/661/80
Most frequent other events
Most frequent other events
EventRocuronium - SugammadexSuccinylcholine
Procedural painInjury, poisoning and procedural complications44/6650/80
Procedural hypotensionInjury, poisoning and procedural complications2/6617/80
NauseaGastrointestinal disorders13/6610/80
VomitingGastrointestinal disorders7/665/80
Incision site painInjury, poisoning and procedural complications5/667/80
Procedural nauseaInjury, poisoning and procedural complications5/663/80
Abdominal painGastrointestinal disorders3/665/80
MyalgiaMusculoskeletal and connective tissue disorders1/665/80

Baseline characteristics

Age, Continuous
Age, Continuous(years)Rocuronium - SugammadexSuccinylcholineTotal
Mean40 ± 1345 ± 1443 ± 14
Sex: Female, Male
Sex: Female, Male(Participants)Rocuronium - SugammadexSuccinylcholineTotal
Female4853101
Male182745
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Soto R, Jahr JS, Pavlin J, Sabo D, Philip BK, Egan TD, Rowe E, de Bie J, Woo T. Safety and Efficacy of Rocuronium With Sugammadex Reversal Versus Succinylcholine in Outpatient Surgery-A Multicenter, Randomized, Safety Assessor-Blinded Trial. Am J Ther. 2016 Nov/Dec;23(6):e1654-e1662. doi: 10.1097/MJT.0000000000000206. PubMed 25768376 ↗
  • Sabo D, Jahr J, Pavlin J, Philip B, Shimode N, Rowe E, Woo T, Soto R. The increases in potassium concentrations are greater with succinylcholine than with rocuronium-sugammadex in outpatient surgery: a randomized, multicentre trial. Can J Anaesth. 2014 May;61(5):423-32. doi: 10.1007/s12630-014-0128-7. Epub 2014 Apr 8. PubMed 24710957 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2008, a primary completion of Dec 2009 and a completion of Dec 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2012, 2 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 10, 2008
First posted
Sep 11, 2008
Start
Nov 2008
Primary completionActual
Dec 2009
CompletionActual
Dec 2009
Results first posted
Mar 20, 2012
Last update
Jun 30, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 30, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00751179
Responsible party
Sponsor
First posted
Sep 11, 2008
Start date
Nov 2008
Primary completion
Dec 2009
Completion
Dec 2009
Results posted
Mar 20, 2012
Last update
Jun 30, 2015

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Rocuronium · Sugammadex · Succinylcholine

Start the discussion